Regulated information

Dynamic first half 2016

2016 Half year Financial Report

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2015 (french version)

The Registration document of Vetoquinol relative to fiscal year 2015, including the Annual financial report relative to fiscal year 2014, was filed with the Autorité des marchés financiers (“the AMF”) on April 26, 2016.

Q1 sales: €85.8M

Vetoquinol posted Q1 2016 sales of €85.8 million, representing organic growth of 7.7%. Changes in exchange rates resulted in a negative currency impact of 2.1%; reported sales for the first three months of 2016 grew by 5.6%.

2015 results sales of reference products up 9.4% ebit up 10.3%

At its meeting on March 18, 2016, the Vetoquinol S.A. Board of Directors reviewed the Group’s results and approved the 2015 financial statements.

2015 sales up 8.7% to €342.6 million

The Vetoquinol Group posted 2015 sales of €342.6 million, up 8.7% on reported data and up 3.8% at constant exchange rates. The Group benefited from a positive currency impact of 4.9% mainly linked to the US dollar, Indian rupee and British pound.

Vétoquinol markets CEFTIOCYL® and KEFLORIL® two new injectable antibiotics for livestock

Lure, December 15, 2010 – In line with recent announcements, Vétoquinol is
launching Ceftiocyl® and Kefloril®, two new injectable antibiotics for livestock.
The products are being brought to market by the Group and its subsidiaries in
both domestic and export markets.

Vétoquinol appoints RÉGIS VIMAL DU MONTEIL Group Finance and Legal Director

November 30, 2010 (Lure, France) – Vétoquinol has appointed Régis Vimal du Monteil as
Group Legal and Financial Director.

Vétoquinol registers its injectable Marbocyl® 2% and Marbocyl® 10% antibiotics in Japan

November 18, 2010 (Lure, France) – Vétoquinol has just obtained Marketing
Authorisation (MA) from Japanese drug authorities for its Marbocyl® 2% and
Marbocyl® 10% antibiotics for livestock, through collaboration with Meiji Seika
Kaisha, Ltd.

Strong Sales in the 3rd Quarter of 2010

Vétoquinol’s revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group’s strategic regions and therapeutic segments.

Mise à disposition ou de consultation du rapport financier semestriel 2010 (french)

Le Rapport financier semestriel 2010 de Vétoquinol peut être consulté ou téléchargé sur
le site Internet de la société : www.vetoquinol.com, rubrique « Investisseurs & Journalistes ».